ArticlemedRxiv : the preprint server for health sciences2026
Outcomes of the three-month weekly isoniazid with rifapentine (3HP) versus the six-month isoniazid preventive therapy (6H) among people newly enrolled in HIV care in western Kenya.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In trials, three-month weekly rifapentine and isoniazid (3HP) showed higher adherence and completion than the six-month daily isoniazid (6H) regimen for TB preventive treatment (TPT). However, programmatic outcome data remain limited. Methodology: We evaluated the TPT cascade among people with HIV (PWH) aged > 15 years newly enrolled in HIV care in western Kenya. Initiation and completion of 6H (Jan to Sept 2022) were compared to 3HP (Oct 2022-Sept 2023) using Chi-square tests. Correlates of non-initiation and non-completion were assessed using Poisson regression with generalized linear models. Mortality within 24 months was evaluated using Cox proportional hazards regression. Results: Of 1,930 PWH (median age 33 years [IQR=27-41]), 65.8% were female, and 19.5% had AHD at enrolment. Overall, 1,922 (99.6%) were screened for active TB, of whom 1,790 (97.5%) were TPT-eligible; 1577 (88.1%) of these initiated TPT. TPT initiation was higher with 3HP than 6H (89.8% vs. 84.2%; p<0.001). TPT completion was similar for 3HP and 6H (89.2% vs. 88.8% p=0.77). TB incidence (per 1,000 person-months) was lower among TPT-completers (0.22; 95% CI 0.15-0.35) than those who neither initiated (4.25; 95% CI 1.77-10.23) nor completed TPT (3.75; 95% CI 2.49-5.64). AHD was associated with higher risk of TPT non-initiation (aRR=2.14; 95% CI 1.59-2.87) and non-completion of both 6H (aRR=2.56; 95% CI: 1.55-4.23) and 3HP (aRR=1.68; 95% CI 1.07-2.63). Conclusions: 3HP increased TPT initiation but did not improve completion rates compared to 6H. Targeted interventions are needed to support 3HP completion, particularly in PWH with AHD. Key points: We compared 3HP and 6H for TB prevention in people with HIV in western Kenya. 3HP led to better initiation and both had high completion rates. Advanced HIV disease affected participation and non-completers faced significant mortality.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.